and in Biological Technology
Navigation Links
and in Biological Technology
DOE awards $377 million in funding for 46 energy frontier research centers
... national laboratories, nonprofit organizations, and private firms across the nation. "As global ... need to reduce our dependence on imported oil and curtail greenhouse gas emissions," said Secretary ... to reduce our dependence on imported oil and curtail greenhouse gas emissions will require ...Microparts interest group workshop
... metrology for miniature components. VSL, NPL, PTB and METAS are collaborating on the project in all ... the development of novel contact, optical and XCT probing techniques, machine calibration, stability, traceability and calibration artefacts. The workshop aims to ...... so long ago only the final products were visible and scientists were forced to gauge the processes ... of technologies that allow for the observation and manipulation of single molecules. A prime example ... Interim Berkeley Lab Director Paul Alivisatos and Ulrich Dahmen, director of Berkeley Lab's ...
KV Pharmaceutical Announces Stockholder Action to Amend By-Laws is Invalid
... notified certain owners of the Company's Class A and Class B Common Stock, as further described below ... with the requirements of the Company's By-Laws and is therefore invalid and not effective. Specifically, on August 5, ...Schering-Plough Shareholders Approve Merger With Merck
... said Fred Hassan, Schering-Plough chairman and CEO. "After six years of transformation under ... colleagues can be very proud of the strengths and diversity we have created. As we move closer to ... we will continue to focus on driving our business and advancing our strong late-stage pipeline until ...Arizona Pain Specialists Contend Recent Vertebroplasty Studies are Misleading
... a significant improvement in patients' pain and ability to function normally. Tory ... data show that this procedure relieves pain and improves patients' quality of life. I have seen amazing results from vertebroplasty in my practice and for my grandmother." Allen Burton, MD, ...REPEL-CV(TM) Adhesion Barrier Receives Endorsement of Kids With Heart
... a biomaterials company engaged in the development and commercialization of anti-adhesion products, ... in the heart becoming attached to the sternum and other surrounding tissue surfaces. The presence of adhesions represents a prevalent and serious complication in secondary surgical ...Volcano Corporation Presentation At Canaccord Adams Conference To Be Webcast
... VOLC), a leader in the development, manufacturing and sales of products for the diagnosis and treatment of coronary and peripheral artery disease, said today that it ...SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results
... ) today reported financial results for the three and six months ended June 30, 2009. Dr. Bruce Morra, SCOLR Pharma's President and CEO, said, "We continue to advance discussions ... have been committing resources to due diligence and preliminary negotiations of license terms. In the ...Novavax Reports Second Quarter 2009 Financial Results
... the six months ended June 30, 2008. Total cash and short-term investments as of June 30, 2009 were ... its balance sheet by raising additional capital and retiring 100% of its convertible debt, and entered into an initial agreement with ROVI ...Kensey Nash Announces Agreement to Acquire Rights to OsseoFit Product
... rights, along with the trademark, inventory and other assets associated with the OsseoFit Bone ... Under the terms of the agreement, the Company and Biomet Sports Medicine agreed to terminate their ... business," commented Joe Kaufmann, President and CEO. "This transaction will allow us to explore a ...... company specializing in nucleic acid therapeutics and delivery, announced today that Jason Fewell, Ph.D., has been promoted from Director of Biology and Pharmacology to Vice-President of Preclinical Research and Development. Dr. Fewell possesses more ...
Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results
... reported financial results for the second quarter and six months ended June 30, 2009. Second ... a net loss of $1,761,887, or $0.13 per basic and diluted share, compared to a net loss of $2,377,440, or $0.19 per basic and diluted share for the same period in 2008. Second ...NeurogesX Reports Second Quarter 2009 Results
... of Qutenza in Europe, Middle East and Africa, including commercialization option and development funding for NGX-1998 and post-marketing studies to support Qutenza EU ...InterMune to Present at Canaccord Adams Conference
... that Dan Welch, Chairman, Chief Executive Officer and President of InterMune, will present at the ... live audio webcast of the presentation, investors and other interested parties may log on to the ... company focused on the research, development and commercialization of innovative therapies in ...AOBO Announces New Product Launch
... health through the development, manufacture and commercialization of a broad range of prescription and over the counter ("OTC") products in China, today ... has launched a new product for the rhinitis and allergy market, called Jingwei Capsules ...Viral Genetics Creates Subsidiary to Develop Cancer Therapy
... with existing treatments such as chemotherapy and radiation therapy to further limit the growth of ... bringing this concept forward into clinic trials and expanding the indications provided by the ... We believe that we finally have the knowledge and tools to turn this concept into a clinical ...American Oriental Bioengineering Reports Second Quarter 2009 Financial Results
... health through the development, manufacture and commercialization of a broad range of prescription and over the counter ("OTC") products in China, today ... demand for the Company's core pharmaceutical and nutraceutical products. Revenue from ...Prix Galien USA Announces 2009 Final Candidates
... Pharmaceutical Agent, Best Biotechnology Product and Best Medical Technology to be recognized at Sept. ... will recognize innovative biopharmaceutical drugs and medical technologies that have made a deep impact ... chronic diseases including cardiovascular disease and ...ALPCO Introduces a Mouse HMW and Total Adiponectin ELISA
... methods for determining mouse HMW adiponectin and was first introduced in a pre-market form in a ... oligomers using protease pretreatment, and the Mouse HMW Adiponectin ELISA kit reflects a ... detection of both high-molecular-weight (HMW) and total adiponectin. The human multimeric ...... at a price to the public of $30.50 per share and $200 million aggregate principal amount of its ... an additional 600,000 shares of its common stock and up to an additional $30 million aggregate ... to purchase additional shares of common stock and convertible notes). All of the shares of common ...
AutoImmune Inc. Reports 2009 Second Quarter Financial Results
... a net loss of $86,000, or $0.01 per share basic and diluted, for the three months ended June 30, ... a net loss of $86,000, or $0.01 per share basic and diluted, for the three months ended June 30, ... net loss was $256,000, or $0.02 per share basic and diluted, compared with net loss of $193,000, or ...ThermoGenesis Announces Expanded Collaboration With Celling Technologies
... supplier of innovative products for processing and storing adult stem cells, today announced an ... marrow products, MXP(TM) MarrowXpress(TM) ("MXP") and Res-Q(TM) 60 BMC ("Res-Q"). Celling is a leading ... of this expanded collaboration, ThermoGenesis and Celling will share in the funding for clinical ...Synthetech Reports First Quarter Fiscal 2010 Results
... sales, mainly to Europe, were $2.9 million and $2.6 million in the first quarters of fiscal 2010 and 2009, respectively. International sales, like ... a more favorable product mix; improved throughput and ...Microbix Sales Grow 22% For Nine Months
... Burn rate significantly reduced and Semen Sexing Technology achieves milestone ... Biosystems Inc. (TSX:MBX) announced strong sales and a significantly reduced burn rate. The third ... retraction that was related to timing of orders and changing exchange rates. The forecast is for ...GenVec Reports Second Quarter 2009 Financial Results
... 30, 2008. Revenues for the three-month and six-month periods ended June 30, 2009 were $3.8 million and $7.6 million, respectively, compared to revenues of $3.9 million and $7.6 million in the comparable prior year ....Vanda Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 10, 2009
... company focused on the development and commercialization of clinical-stage product ... Mihael H. Polymeropoulos, M.D., President and Chief Executive Officer, will host a conference ... below shortly before the 10:00 AM start time and ask for the Vanda Pharmaceuticals conference call ...... as Vice President, Chief Financial Officer and treasurer. Mr. Driscoll will report to Dr. Rahul Singhvi, Novavax's President and Chief Executive Officer. Previously Mr. Driscoll served as Chief Financial Officer, and ...
... software tools used for design, selection and procurement of chemical compound libraries. The ... ) comprehensive suite of virtual screening and selection tools and industry-leading searchable database of over 60 ...
... markets. Michael C. Ferrara, President and Chief Executive Officer, and Peter F. Byczko, Vice President of Finance and Chief Accounting Officer, will host a conference ...
ThermoGenesis Provides Update on Fiscal 2009 Results
... supplier of innovative products for processing and storing adult stem cells, said today that it ... equipment purchases of BioArchive(R) Systems and reduced sales of AXP(R) AutoXpress(TM) ("AXP") ... of $2.8-$3.3 million, subject to final audit and adjustments . Contributing to the fourth ...InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
... results from operations for the second quarter and six months ended June 30, 2009. InterMune ... Dan Welch, Chairman, Chief Executive Officer and President of InterMune, said, "The last several ... have been exceptionally productive for InterMune and the coming months promise to be even more so. ...SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights
... of MassARRAY((R)) systems. Cost of product and service revenue for the second quarter of 2009 ... to hardware or platform products. Research and development expenses were $10.2 million for the ... for the same period in the prior year. Research and development expenses for the second quarter of ...OncoGenex Reports Second Quarter 2009 Financial Results
... 2009 at 4:30 p.m. Eastern Time BOTHELL, WA, and VANCOUVER, Aug. 6 /PRNewswire-FirstCall/ - ... financial results for the second quarter and six months ended June 30, 2009 and reviewed the Company's highlights for the second ...Telik Announces Second Quarter 2009 Financial Results
... ended June 30, 2009, total operating costs and expenses were $6.3 million, compared with $11.0 ... February 2009, reduced research, clinical trial and related expenses and lower stock compensation expense. For the ...... Inc. Is Pleased To Announce The Launch Of Its New and Improved Website. The New Site Provides Users With A Comprehensive Overview Of Pace Analytical and Incorporates A More User-Friendly Design Layout To Enhance Functionality and Navigation. The Site Also Offers An Expanded ...
Ratcliff Adds Architect John Sealander to Healthcare Practice Group
... the award-winning architecture, planning and interiors firm, added John E. Sealander, AIA, ... ) provides a broad array of design and planning services to healthcare, academic, and civic clients throughout the Western United ...... of its conference call to discuss these results and recent operating highlights on Tuesday, August ... from approximately 10am EDT on Tuesday, August 11 and for one week thereafter. The dial-in replay numbers are: 1-800-475-6701 in the U.S., and +1-320-365-3844 for those calling from outside ...
The Law Offices of Brian D. Witzer Wins 6+ Million Dollar Verdict
... that the Defendant, an osteopathic physician and registered pharmacist, prescribed it to her for gout. Plaintiff disputed the diagnosis and alleged that she did not have gout. The doctor claimed that she told him she had gout and described pain in her toe consistent with gout. ...... potent anti-cancer activity in colon and breast cancer models for the company's first ... responsible for driving tumor initiation, growth and recurrence. Research published in Cell Stem ... Cancer Biology of OncoMed Pharmaceuticals and a co-author of the paper. "In models of ...
Other ContentspleiotropypleurapleurapointpointpointpointpointpointpointpointpointpointpolaritypolaritypolaritynucleinucleinucleinucleinucleinucleipolarpolarpolarpolarpolarOther Tags
(Date:11/24/2009)...understanding how sounds associated with Navy sona...if they hear it at all. , The same type of large... detect flaws in the space shuttle,s behemoth soli...inside the giant head of a whale. The scans are pr...hale,s hearing anatomy using a breakthrough method...
(Date:11/24/2009)...dical Toxicology (ACMT) have signed an agreement t...f Medical Toxicology (JMT), the official journal ...iously published by the University of Pennsylvania...an international, peer-reviewed journal, is dedica...al toxicology. The quarterly journal focuses on t...
(Date:11/24/2009)... research on bacterial communities throughout six ...temporal patterns, suggesting that scientists coul...climate change in the polar regions. The study, pu...nal Academy of Sciences Early Edition, shows that...ynchronously over time, correlating with seasonal ...
Breaking Biology News(10 mins):Rocket science leads to new whale discovery 2Springer and the American College of Medical Toxicology to work together 2Researchers establish common seasonal pattern among bacterial communities in Arctic rivers 2Abbott Receives CE Mark for Companys Next Generation XIENCE PRIME 28TM 29 Drug Eluting Stent Advancing Leadership Position 49720 1Abbott Receives CE Mark for Companys Next Generation XIENCE PRIME 28TM 29 Drug Eluting Stent Advancing Leadership Position 49720 2Abbott Receives CE Mark for Companys Next Generation XIENCE PRIME 28TM 29 Drug Eluting Stent Advancing Leadership Position 49720 3Phyhealth Issues 2008 Audited Financial Statements and Provides Business Update 49717 1Phyhealth Issues 2008 Audited Financial Statements and Provides Business Update 49717 2Phyhealth Issues 2008 Audited Financial Statements and Provides Business Update 49717 3CutisPharma Inc Receives Verified Accreditation for Wholesale Distributors from the National Association of Boards of Pharmacy for Woburn Facility 12737 1CutisPharma Inc Receives Verified Accreditation for Wholesale Distributors from the National Association of Boards of Pharmacy for Woburn Facility 12737 2(Date:11/29/2009)... Moravia,s Nanjing-based Service Delivery ... , Brno, Czech Republic (...on solution provider, is pleased to announce its p...009, to be held in Nanjing, China, on November 30,...ion-based companies that have established and grow...
(Date:11/29/2009)...ng mannequins to teach doctors-in-training how to ...y to improve their skills without compromising pat...m Henry Ford Hospital. , The study shows that th...ble tool to improve medical residents, knowledge, ...e more common ultrasound-guided procedures, includ...
(Date:11/29/2009)...e get blamed for something leads to more self-defe...UNDAY, Nov. 29 (HealthDay News) -- The blame game ...n the target is innocent. , Researchers found t... a problem, even if it,s an unfair accusation, the... too. , "When we see others protecting their e...
(Date:11/29/2009)... "The YogaForce A-Line Athletic Mat i...Andrew Weil, M.D., author and physician best known...tegrative medicine. Go to www.yogaforce.com and... the gift list. , San Fra...me for the holidays, the YogaForce newly patented,...
(Date:11/28/2009)...CAGO, Nov. 28 Get ready for adv...he clinical routine when Siemens introduces ... and Annual Meeting of the Radiological Society of... 3 at McCormick Place (Booth #825, East Building/L... via , Siemens, new imaging software for mult...
Breaking Medicine News(10 mins):Health News:Moravia Worldwide to Participate in the 5th EU-China Business Summit 2009 in Nanjing China 2Health News:Simulated training for ultrasound-guided procedures improves safety without risk to patients 2Health News:When Accusations Start to Fly, They Multiply 2Health News:The YogaForce A-Line Mat Provides The Perfect Solution For Fitness Needs 2Health News:The YogaForce A-Line Mat Provides The Perfect Solution For Fitness Needs 3Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 2Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 3Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 4Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 5[1] Moravia Worldwide to Participate in the 5th EU-China Business Summit 2009 in Nanjing China [1] Simulated training for ultrasound-guided procedures improves safety without risk to patients[1] When Accusations Start to Fly, They Multiply[0] The YogaForce A-Line Mat Provides The Perfect Solution For Fitness Needs [1] Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via
CefotaximeDisplaceCheeksThighsDimpledCrispsMalnourishmentPerformsTMCHComparesPsychoneurobiologyUndercookedEndorsingSquandered
Other Tagsenhancement 2enhancement 3graduates 2graduates 3graduates 4lacking 2lacking 3lacking 4lacking 5lacking 6lacking 7lacking 8teaching 2demonstration 2demonstration 3demonstration 4
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |